Sight Sciences, Inc. (SGHT) Stock

Sight Sciences, Inc. is a pioneering ophthalmic medical device company dedicated to advancing the field through innovative surgical and nonsurgical technologies aimed at treating various eye diseases. The company specializes in developing and commercializing cutting-edge products designed to address critical needs in ophthalmology.

Among its flagship offerings is the OMNI Surgical System, a therapeutic device utilized by ophthalmic surgeons to effectively reduce intraocular pressure in adult glaucoma patients. This system represents a significant advancement in surgical treatment options for individuals suffering from this common eye condition.

In addition to the OMNI Surgical System, Sight Sciences, Inc. has introduced the TearCare System, a groundbreaking wearable eyelid technology specifically designed for the treatment of dry eye disease (DED). This innovative system provides ophthalmologists and optometrists with a powerful tool to manage and alleviate symptoms associated with DED, enhancing patient care and comfort.

Headquartered in Menlo Park, California, Sight Sciences, Inc. was founded in 2010. The company distributes its products through a network of sales representatives and distributors, serving hospitals, medical centers, and eyecare professionals across the United States. With a commitment to innovation and patient-centered care, Sight Sciences continues to lead the way in transforming ophthalmic treatment options and improving outcomes for patients world wide.